Articles by Lori Clapper

  1. Actavis, Allergan Ink $66B Acquisition Deal 11/20/2014

    Actavis inked a $66 billion deal to acquire Allergan on Monday, a move which will create a top 10 pharmaceutical company.

  2. Servier Inks $1B Deal To Co-Develop Implantable Pump To Treat Type 2 Diabetes 11/18/2014

    French pharmaceutical company Servier has partnered with start-up company Intarcia Therapeutic to develop and commercialize Intarcia’s drug-loaded implantable pump for those suffering from diabetes. It’s a deal that could be worth $1 billion overall, Intarcia announced last week.

  3. AbbVie Hepatitis C Treatment Cures 97 Percent Of Liver Transplant Patients 11/14/2014

    AbbVie announced data from its research in Hepatitis patients with HIV-1 this week at the Liver Meeting 2014. According to the study, 33 out of 34 patients treated with AbbVie’s experimental antiviral cocktail of ombitasvir, ritonavir, dasabuvir, ABT-450, were cured of the virus after 24 weeks.

  4. Reckitt Benckiser Pharmaceuticals To Demerge, Re-Brand As Indivior By End Of Year 10/29/2014

    U.K.-based Reckitt Benckiser Group expects its demerger of Reckitt Benckiser Pharmaceuticals (RBP) will be completed before December 2014. This move was originally announced in July 2014.

  5. Celgene, Sutro Strike Partnership For ADC R&D 10/29/2014

    Celgene Corporation and Sutro Biopharma have entered into a strategic collaboration and option agreement to discover and develop multispecific antibodies and antibody drug conjugates (ADCs).

  6. Fujifilm Makes Leap From Photography To Ebola Treatment 10/28/2014

    Japan's Fujifilm announced Monday it is ready and willing to scale-up manufacture of its anti-influenza drug Avigan to help treat more Ebola patients worldwide.

  7. AbbVie, Shire “Break Up” As Result Of New Tax Inversion Rules 10/23/2014

    AbbVie has pulled the plug on its deal to buy out U.K.-based drug maker Shire this week, in the wake of new rules the U.S. government plans to implement to govern overseas acquisitions. The proposed acquisition has been described by Bloomberg as the “biggest U.S. tax inversion” to date, as AbbVie was set to purchase Shire for $52 billion and move its headquarters to the U.K. in the name of lower taxes.

  8. WHO Certifies 3 Nigerian Pharma Companies For Drug Manufacturing 10/17/2014

    The World Health Organization (WHO) has given three Nigerian pharmaceutical manufacturing companies the go-ahead to produce international drugs: Evans Pharmaceutical, May & Baker Pharmaceutical, and Chi Pharmaceutical, The Guardian reported Thursday. 

  9. Uniform National Serialization Strategy To Negate State Strategies 10/13/2014

    The U.S. Food and Drug Administration (FDA) has divulged new information about a planned nation-wide serialization system aimed at preventing counterfeit drugs from reaching U.S. customers, Regulatory Affairs Professionals Society (RAPS) reports.

  10. Eisai Makes Strides With Cancer, Alzheimer's Drugs 10/13/2014

    Eisai announced today that its anticancer agent Halaven (eribulin mesylate) was approved by the Australian Department of Health and Aging, to treat patients with locally or advances metastatic breast cancer.